Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 19;17(1):1.
doi: 10.1186/s13030-023-00261-w.

Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality

Anna Rychter  1 , Joanna Miniszewska  2 , Joanna Góra-Tybor  3
Affiliations

Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality

Anna Rychter et al. Biopsychosoc Med. .

Abstract

Background: The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are non-compliant. Recently there is growing evidence that personality traits may influenced the tendency for non-adherence to treatment in patients with chronic diseases. As far as we know, such a relationship in patients with CML has not been examined, yet. The aim of our study was to determine if personality traits favor non-adherence to treatment recommendations. We investigated the relationship between five-factor model personality factors (conscientiousness, neuroticism, agreeableness, extraversion, and openness) and medication non-adherence. We also checked if the patients with type A and type D personality, were at higher risk of poor medication adherence.

Methods: The following tools were used: self-constructed survey, the NEO-Five Factor Inventory, the Framingham Type A Scale, the D-Scale 14. The study included 140 CML patients treated with imatinib, dasatinib, or nilotinib.

Results: 39% of patients reported skipping at least one dose of medication in the month prior to follow-up visit. 51% admitted to skipping such doses from the start of their treatment to the time at which our assessment was performed. We did not find any relationship between the mean values of the analyzed factors of the Big Five (neuroticism, extraversion, openness, agreeableness, conscientiousness) and adherence. However, our analysis revealed that CML patients who admitted to missing doses of drugs during the entire course of treatment demonstrated greater intensity of type A personality traits (p = 0.020). Regarding both factors of type D personality, it was revealed that higher level of negative affectivity significantly decreased the adherence (p = 0.020).

Conclusion: The results of our study indicate that screening for type D and A personalities may help to identify patients who are at higher risk of poor medication adherence.

Keywords: Adherence; Chronic myeloid leukemia; Personality traits; Type A personality; Type D personality.

PubMed Disclaimer

Conflict of interest statement

Author JGT has received speaker and consultancy honorariums from Novartis, BMS, Incyte, and Pfizer. The remaining authors report no conflicts of interest.

Similar articles

See all similar articles

References

    1. Noens L, van Lierde MA, de Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11. doi: 10.1182/blood-2008-12-196543. - DOI - PubMed
    1. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27:3445–51. doi: 10.1200/JCO.2008.19.2419. - DOI - PMC - PubMed
    1. Ibrahim A, Eliasson L, Apperley J, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood. 2011;117:3733–6. doi: 10.1182/blood-2010-10-309807. - DOI - PMC - PubMed
    1. Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107:904–9. doi: 10.1038/bjc.2012.348. - DOI - PMC - PubMed
    1. Jabbour E, Kantarjian H, Eliasson L, Cornelison M, Marinet D. Patent adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012;87:687–91. doi: 10.1002/ajh.23180. - DOI - PubMed